Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors

NCT02484638 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

25

Enrollment

INDUSTRY

Sponsor class

Stopped Business decision non-safety related.

Conditions

Hemophilia A With Inhibitors
Hemophilia B With Inhibitors

Interventions

DRUG: CSL689
DRUG: Eptacog alfa (activated)

Sponsor

CSL Behring